Treatment of Schizophrenic Patients With Ziprasidone

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00579670
• Date of registration: 20/12/2007
• Primary sponsor: Pfizer
• Public title: Treatment of Schizophrenic Patients With Ziprasidone TRITON
• Scientific title: Treatment of Schizophrenic Patients With Geodon; Capsules/Oral Suspension/Solution for Injection (Ziprasidone)
• Date of first enrolment: October 2007
• Target sample size: 450
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00579670
• Study type: Observational
• Study design: Observational Model: Cohort, Time Perspective: Prospective

Countries of recruitment

Greece

Contacts

• Name: Pfizer CT.gov Call Center
• Affiliation: Pfizer

Key inclusion & exclusion criteria

Inclusion Criteria:

- Usual clinical practice of physician

Exclusion Criteria:

- None



Age minimum: 18 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Schizophrenia

Intervention(s)

Drug: Ziprasidone

Primary Outcome(s)

Summary of Metabolic Risk Factors [Time Frame: Baseline]

Summary of Most Frequently Used Concomitant Drug Treatments [Time Frame: Baseline]

Summary of Schizophrenia [Time Frame: Baseline]

Secondary Outcome(s)

Number of Participants Answering the Question "As a Result of Taking This Medication, do You Experience Any Side Effects at All?" [Time Frame: Week 12]

Number of Participants Answering the Question "How Bothersome Are the Side Effects of the Medication You Take to Treat Your Condition?" [Time Frame: Week 12]

Number of Participants Answering the Question "How Certain Are You That the Good Things About Your Medication Outweigh the Bad Things?" [Time Frame: Week 12]

Number of Participants Answering the Question "How Convenient or Inconvenient is it to Take the Medication as Instructed?" [Time Frame: Week 12]

Number of Participants Answering the Question "How Easy or Difficult is it to Plan When You Will Use the Medication Each Time?" [Time Frame: Week 12]

Number of Participants Answering the Question "How Easy or Difficult is it to Use the Medication in Its Current Form?" [Time Frame: Week 12]

Number of Participants Answering the Question "How Satisfied or Dissatisfied Are You With the Ability of the Medication to Prevent or Treat Your Condition?" [Time Frame: Week 12]

Number of Participants Answering the Question "How Satisfied or Dissatisfied Are You With the Amount of Time it Takes the Medication to Start Working?" [Time Frame: Week 12]

Number of Participants Answering the Question "How Satisfied or Dissatisfied Are You With the Way the Medication Relieves Your Symptoms?" [Time Frame: Week 12]

Number of Participants Answering the Question "Overall, How Confident Are You That Taking This Medication is a Good Thing?" [Time Frame: Week 12]

Number of Participants Answering the Question "Taking All Things Into Account, How Satisfied or Dissatisfied Are You With This Medication?" [Time Frame: Week 12]

Number of Participants Answering the Question "To What Degree Have Medication Side Effects Affected Your Overall Satisfaction With the Medication?" [Time Frame: Week 12]

Number of Participants Answering the Question "To What Extent do the Side Effects Interfere With Your Mental Function (ie, Ability to Think, Stay Awake, Etc)?" [Time Frame: Week 12]

Number of Participants Answering the Question "To What Extent do the Side Effects Interfere With Your Physical Health and Ability to Function (ie, Ability to Think Clearly, Stay Awake, Etc)?" [Time Frame: Week 12]

Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I) [Time Frame: Week 12]

Number of Participants With Categorical Scores on Clinical Global Impression of Severity (CGI-S) [Time Frame: Baseline, Week 12]

PANSS - Composite Subscale [Time Frame: Baseline, Week 12]

PANSS - Negative Subscale [Time Frame: Baseline, Week 12]

Percent Change From Baseline to Final Visit in Body Weight [Time Frame: Baseline, Week 12]

Positive and Negative Syndrome Scale (PANSS) - Positive Subscale [Time Frame: Baseline, Week 12]

Secondary ID(s)

A1281156

Source(s) of Monetary Support

Please refer to primary and secondary sponsors